Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life.

Autor: Uhlmann RE; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany.; Graduate School of Cellular and Molecular Neuroscience, University of Tübingen, Tübingen, Germany., Rother C; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany.; Graduate School of Cellular and Molecular Neuroscience, University of Tübingen, Tübingen, Germany., Rasmussen J; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany.; Graduate School of Cellular and Molecular Neuroscience, University of Tübingen, Tübingen, Germany., Schelle J; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany., Bergmann C; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany., Ullrich Gavilanes EM; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; Graduate School of Cellular and Molecular Neuroscience, University of Tübingen, Tübingen, Germany., Fritschi SK; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany., Buehler A; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany., Baumann F; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany., Skodras A; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany., Al-Shaana R; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany., Beschorner N; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany., Ye L; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany., Kaeser SA; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany., Obermüller U; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany., Christensen S; Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark., Kartberg F; Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark., Stavenhagen JB; Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark., Rahfeld JU; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany., Cynis H; Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle, Germany., Qian F; Biogen Inc., Cambridge, MA, USA., Weinreb PH; Biogen Inc., Cambridge, MA, USA., Bussiere T; Biogen Inc., Cambridge, MA, USA., Walker LC; Department of Neurology and Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA., Staufenbiel M; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany., Jucker M; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. mathias.jucker@uni-tuebingen.de.; German Center for Neurodegenerative Diseases, Tübingen, Tübingen, Germany. mathias.jucker@uni-tuebingen.de.

Publikováno v: Nature neuroscience [Nat Neurosci] 2020 Dec; Vol. 23 (12), pp. 1580-1588. Date of Electronic Publication: 2020 Nov 16.

Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration.

Autor: Ryu JK; Gladstone Institutes, San Francisco, CA, USA., Rafalski VA; Gladstone Institutes, San Francisco, CA, USA., Meyer-Franke A; Gladstone Institutes, San Francisco, CA, USA., Adams RA; Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA., Poda SB; Lundbeck Research USA, Paramus, NJ, USA., Rios Coronado PE; Gladstone Institutes, San Francisco, CA, USA., Pedersen LØ; H. Lundbeck A/S, Copenhagen, Denmark., Menon V; Lundbeck Research USA, Paramus, NJ, USA., Baeten KM; Gladstone Institutes, San Francisco, CA, USA., Sikorski SL; Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA., Bedard C; Gladstone Institutes, San Francisco, CA, USA., Hanspers K; Gladstone Institutes, San Francisco, CA, USA., Bardehle S; Gladstone Institutes, San Francisco, CA, USA., Mendiola AS; Gladstone Institutes, San Francisco, CA, USA., Davalos D; Gladstone Institutes, San Francisco, CA, USA.; Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Machado MR; Gladstone Institutes, San Francisco, CA, USA., Chan JP; Gladstone Institutes, San Francisco, CA, USA., Plastira I; Gladstone Institutes, San Francisco, CA, USA.; Institute of Molecular Biology and Biochemistry, Medical University Graz, Graz, Austria., Petersen MA; Gladstone Institutes, San Francisco, CA, USA.; Division of Neonatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA., Pfaff SJ; Small Molecule Discovery Center, Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA., Ang KK; Small Molecule Discovery Center, Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA., Hallenbeck KK; Small Molecule Discovery Center, Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA., Syme C; Gladstone Institutes, San Francisco, CA, USA., Hakozaki H; National Center for Microscopy and Imaging Research, University of California, San Diego, La Jolla, CA, USA., Ellisman MH; National Center for Microscopy and Imaging Research, University of California, San Diego, La Jolla, CA, USA.; Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA., Swanson RA; Neurology Service, San Francisco Veteran Affairs Medical Center, San Francisco, CA, USA.; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Zamvil SS; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Arkin MR; Small Molecule Discovery Center, Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA., Zorn SH; Lundbeck Research USA, Paramus, NJ, USA., Pico AR; Gladstone Institutes, San Francisco, CA, USA., Mucke L; Gladstone Institutes, San Francisco, CA, USA.; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Freedman SB; Gladstone Institutes, San Francisco, CA, USA., Stavenhagen JB; H. Lundbeck A/S, Copenhagen, Denmark., Nelson RB; Lundbeck Research USA, Paramus, NJ, USA., Akassoglou K; Gladstone Institutes, San Francisco, CA, USA. kakassoglou@gladstone.ucsf.edu.; Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA. kakassoglou@gladstone.ucsf.edu.; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. kakassoglou@gladstone.ucsf.edu.

Publikováno v: Nature immunology [Nat Immunol] 2018 Nov; Vol. 19 (11), pp. 1212-1223. Date of Electronic Publication: 2018 Oct 15.

Development of a Cell-Based Assay to Assess Binding of the proNGF Prodomain to Sortilin.

Autor: Malik I; Department Neurodegeneration, H. Lundbeck A/S, Ottiliavej 9, 2500, Valby, Denmark., Christensen S; Department Neurodegeneration, H. Lundbeck A/S, Ottiliavej 9, 2500, Valby, Denmark., Stavenhagen JB; Department Neurodegeneration, H. Lundbeck A/S, Ottiliavej 9, 2500, Valby, Denmark., Dietz GPH; Department Neurodegeneration, H. Lundbeck A/S, Ottiliavej 9, 2500, Valby, Denmark. gdietz@gwdg.de.

Publikováno v: Cellular and molecular neurobiology [Cell Mol Neurobiol] 2018 May; Vol. 38 (4), pp. 827-840. Date of Electronic Publication: 2017 Oct 24.